Form 8-K - Current report:
SEC Accession No. 0001213900-25-064869
Filing Date
2025-07-17
Accepted
2025-07-17 07:01:40
Documents
14
Period of Report
2025-07-17
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0249257-8k_aldeyra.htm   iXBRL 8-K 27265
2 ALDEYRA THERAPEUTICS, INC. PRESS RELEASE DATED JULY 17, 2025 ea024925701ex99-1_aldeyra.htm EX-99.1 13536
6 GRAPHIC ex99-1_001.jpg GRAPHIC 3850
  Complete submission text file 0001213900-25-064869.txt   217203

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE aldx-20250717.xsd EX-101.SCH 3011
4 XBRL LABEL FILE aldx-20250717_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE aldx-20250717_pre.xml EX-101.PRE 22356
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0249257-8k_aldeyra_htm.xml XML 3688
Mailing Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421
Business Address 131 HARTWELL AVENUE SUITE 320 LEXINGTON MA 02421 781-761-4904
Aldeyra Therapeutics, Inc. (Filer) CIK: 0001341235 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36332 | Film No.: 251128797
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)